Table 2.
N | % | |
---|---|---|
Antibiotics usually available for pelvic surgery * | ||
Aminoglycosides (e.g., gentamicin/tobramycin) | 31 | 78% |
Quinolones (e.g., ciprofloxacin) | 31 | 78% |
Second-generation cephalosporins (e.g., cefuroxime) | 15 | 38% |
Third-generation cephalosporins (e.g., ceftriaxone) | 22 | 55% |
"Rescue" antibiotics for multi-resistant organisms (e.g., imipenem) | 2 | 5% |
Factors influencing availability of antibiotics^ | ||
Market factors: drug availability and hospital budget | 12 | 30% |
Hospital formulary set by administration | 11 | 28% |
Ministry of Health's essential drug list | 8 | 20% |
Donation from partners | 4 | 10% |
Other | 4 | 10% |
No response | 1 | 3% |
Use of prophylactic antibiotics^ | ||
For every fistula case | 23 | 58% |
For selected fistula cases | 14 | 35% |
Never | 2 | 5% |
No response | 1 | 3% |
Most important factor in choice of prophylactic antibiotics^ | ||
Recommendations of medical literature | 9 | 23% |
Surgeon training in vesicovaginal fistula surgery | 9 | 23% |
Availability | 7 | 18% |
Personal choice | 5 | 13% |
Cost | 2 | 5% |
Does not use prophylactic antibiotics | 1 | 3% |
Other | 7 | 18% |
* Multiple responses allowed; percentages exceed 100%.
^ Exceeds 100% due to rounding.